The co-founder of a specialty pharmacy that was at the center of a deadly national meningitis outbreak in 2012 pleaded no contest to involuntary manslaughter in Michigan, authorities said Tuesday.

Under a deal, Barry Cadden’s prison sentence of 10 to 15 years will be served at the same time as his current 14 1/2-year federal sentence for fraud and other crimes, Attorney General Dana Nessel said.

Cadden was co-founder of New England Compounding Center in Massachusetts, which specialized in making drugs for certain treatments and supplying them to doctors across the U.S.

About 800 patients in 20 states were sickened with fungal meningitis or other infections, and about 100 died, after receiving injections of mold-tainted steroids, mostly for back pain, investigators said.

Cadden appeared Monday in Livingston County court, 65 miles (104.6 kilometers) northwest of Detroit. He pleaded no contest to 11 counts of involuntary manslaughter, one charge each for the number of people in Michigan who died, Nessel said.

Cadden had been awaiting trial on second-degree murder charges before the plea deal. A no-contest plea is treated the same as a guilty plea for sentencing purposes. He will return to court on April 18.

READ MORE James Crumbley is up next as 2nd parent to stand trial in Michigan school shooting Iowa Democrats were forced to toss the caucus. They’ll quietly pick a 2024 nominee by mail instead Divided Michigan GOP finds common ground in awarding all its presidential delegates to Trump

“Patients must be able to trust their medications are safe, and doctors must be assured they aren’t administering deadly poison,” Nessel said.

Messages seeking comment from Cadden’s attorney weren’t immediately returned Tuesday.

A similar case against pharmacist Glenn Chin is pending, records show. His next court hearing is scheduled for March 15.

Cadden and Chin were charged in Michigan in 2018, though their cases moved slowly because of separate federal prosecutions, appeals and other issues.

___

Follow Ed White on X, formerly Twitter: @edwritez

Disclaimer: The copyright of this article belongs to the original author. Reposting this article is solely for the purpose of information dissemination and does not constitute any investment advice. If there is any infringement, please contact us immediately. We will make corrections or deletions as necessary. Thank you.